ABSTRACf. A striking clinical phenomenon of cystic fibrosis is the heterogeneous disease expression. It must therefore be assumed that the nature of the mutations associated with cystic fibrosis might partly determine the phenotypic manifestations. The relation between the cystic fibrosis mutations .6.F508, R553X, and 3905insT and clinical parameters such as sweat test electrolytes , age at chronic Pseudomonas aeruginosa COlonization, Chrisp inNorman x-ray scores, and relative underweight have been investigated in 45 patients homozygous for . 6 .F508 (.6.F2), in 12 compound heterozygotes for . 6 .F508/R553X (.6.F1/ RX1), in three R553X homozygotes (RX2), and in 13 patients compound heterozygous for . 6 .F508/3905insT (.6.F16). We have found significant differences between the genetically defined subgroups concerning the mean age at onset and the cumulative incidence of chronic P. aeruginosa colonization and Chrispin-Norman x-ray scores. The significant results as well as some trends regarding the relati ve underweight demonstrate a milder clinical course in R553X heterozygotes and more severe disease in the .6.F16 group compared to .6.F508 homozygotes. The three patients homozygous for R553X presented with a two-stage course showing mild progression before P. aeruginosa infection and as severe a course as the .6.F16 patients after P. aeruginosa colonization at the age of 12 y. The findings presented here indicate that specific mutations can influence the severity and progression of the disease, implicating the importance of mutation and haplotype analyses. However, wide variations within the genetically homogeneous subgroups illustrate that other determinants of the clinical status do exist. (Pediatr Res 32: 175-178, 1992) Abbreviations CF is the most commo n severe autosomal recessive genetic disorder in Caucasian populations, with an incidence of about 1 in 2000 live births, implying a carrier frequency of about 1 in 22. The fundamental defect in CF appears to be a dysfunction of exocrine gland epithelia leading to abnormal secretions that cause obstruction of organ ducts (1) . CF is clinically characterized by chronic airway infection and bronchiectasis, pancreatic insufficiency with malabsorpti on and impaired growth, abnormalities of the intestine (meconium ileus) and the reprodu ctive organs (azoospermia, low female fertility), and elevated sweat chloride concent rations (2) . The disease process is generally slow, but incessant , so that the median survival of patients receiving optimum treatment is 25-30 y (3). Although the majority of patients follow a classic clinical course, the manifestations and severity of CF vary considerably, and the genetic basis for the clinical heterogeneity is still unknown.
A series of reports published in 1985 demonstrated mapping of the CF gene to the long arm of chromosome 7 (4-6). The region containing the gene was defined by cloning CpG-rich islands of DN A, as well as by chromoso me jumping and walking (7, 8) . In 1989, the gene was finally cloned spanning about 250 kb of genomi c DNA. It encodes a protein of 1480 amino acids called the CFTR. The functional regions of the CFTR protein are two NBF, a regulatory domain containing ma ny possible pho sphorylation sites, and two hydrophobic regions that interact with cell membranes. The specific role of CFTR in CI transport remains unre vealed. However, recent data show that expression of intact CFTR, but not of a mutant form, corrects the CF defect, demonstrating a causal relationship between mutations in the CFTR gene and defective Cl transport and enabling furth er investigations on the function of the protein (9, 10) . Th e most common mutation has been found to be l>F508, a 3-bp deletion in exon 10, which results in the loss of a phen ylalanine residue at position 508 in the putative first NBF (11-13). More than a hundred mutations have been detected on CF chromosomes so far. Some of them that have recently been published demonstrate association with milder disease phenotypes (14-1 9). We previously reported on DN A marker haplotypes of restriction fragment length polymorphi sms flanking the CF gene as well as on l>F508 and R553X frequencies in CF families of Switzerland (20, 2 1). T herefore, we present here the mutation and haplotype relation to some clinical manifestations of our CF patients to pro vide further support to a greater und erstandi ng of the nature of the mut ations associated with CF that might influence the phenotypic expression of the disease. Clinical parameters such as onset of chronic Pseudom onas aeruginosa infection, lung involvement evaluated by chest x-ray scores, weight, and sweat electrolyte levels were examined. The two-tailed Mann-Whitney U test was used to compare continuous data , allowing for nonnormal distributions and small subgroup sizes. The Spearman rank correlation coefficient was defined for correlation analysis. Regression was calculated for simple linear and polynomial regression. The cumulative incidence of chronic P. aeruginosa infection was calculated according to Pedersen et al. (24) .
DNA from 73 patients was analyzed, involving 146 chromosomes. Forty-five patients were found to be homozygous for the DoF508 deletion (DoF2). The new detected 3905insT mutation of exon 20 (manus cript in preparation) and the R553X mutation have turned out to be the second and third most common mutations in Switzerland, showing strong linkage to haplot ype 6 and 3, respectively. Three patients presenting with genotype 33 were homozygous for R553X (RX2), 12 demonstrated heterozygosity for DoF508 and R553X (DoFI /RX I), and 13 patients were compo und heterozygous for DoF508 and 3905insT related to haplot ype 6 (DoFI6).
The following data and figures present the relation between parameters of the clinical course and the specific CF mutations DoF508 , R553X, and 3905insT. The number of patients with available data are given in parentheses.
The The diagnosis had been previously confirmed in each patient by typical clinical symptoms and/or family history of CF together with at least two abnormal sweat tests measuring Na as well as Cl concentrations. Pulmonary involvement was biannually established by chest x-rays evaluated by the Chrispin and Norman score (22) . Onset of chronic P. aeruginosa infection was defined as continuous culture of the bacteria from sputum for 6 mo. All patients required pancreatic enzyme supplementation since the date of diagnosis. To evaluate the effect of or the resistance to the enzyme treatment, the patients ' weight and height were determined twice a year and the relative underweight was calculated (23) .
DNA extraction from whole blood, restriction enzyme digestion, Southern blotting, and hybridization using oligo-labeled probes were performed as described before (20) .
Restriction fragment length polymorph isms were determined for the XV2c/TaqI, KMI9/PstI, MP6d9/MspI, and J3.11/MspI probes, and haplotypes were constru cted using the CF patients ' genotypings to establish phase. The larger allele detected by each probe was denoted as 1, the smaller as 2. The haplotypes for The DoF508 mutation defined by a three-base deletion resulting in the loss of phenylalanine residue 508 in exon 10 was identified by amplification of genomic DNA by polymerase chain reaction followed by vertical electrophoresis in a 12% polyacrylamide gel and ethidium bromide staining (21) . The presence of R553X and 3905insT was tested by amplification of exons II and 20 followed either by digestion of the amplification product by the restriction enzyme Hin cH or by sequencing of the single-strand ed po lymerase chain reaction product. Tables I and 2 present the course of Chrispin-Norman x-ray (Table I) . Patients with the 3905insT mutation showed higher scores (NS) than~F2 patients in all age groups except at the age of 8 y, when they were the same in both patient groups (Table I) . Comparison between the compound heterozygotes (~F I /RXI and~FI6) demonstrates higher scores in~F 16 patients in all age groups, with the difference reaching significance at the age of 12 y (p = 0.03) ( Table I) . The three RX2 patients seemed to be in good condition up to the age of 8 y, but showed impressive progress of lung disease from the age of 12 y, presenting with higher scores (16 y p = 0.04) than did F2 patients (Table I) . Underweight did not express significant differences between the genetically defined subgroups because of very large standard deviations. However, the tendencies are the same as for x-ray scores:~F 16 patients are the most underweight, and R553X patients develop mild underweight during the 1st decade, but thereafter dramatically increase the underweight up to 28.7% at the age of 20 y (Table 2) .
Sex differences have been tested for each of the four clinical parameters and no statistical significance has been found .
Progression in lung disease and gastrointestinal complications are determinants of the course in CF patients that leads to death in adolescence or early adulthood in the majority of these patients. CF presents a high degree of clinical heterogeneity, which may be caused, in part, by different mutations. Therefore, clinical characterization of each combination of compound heterozygotes as well as of homozygotes for any mutation is of great importa nce.
In this study, the heterogeneity of the CF phenotype was assessed in quant itative terms such as the age of chronic P. aeruginosa infections, x-ray scores, relative underweight, and sweat test values to allow statistical testing. The sweat test provides the most reliable basis for diagnosing CF, whose characteristics are elevated Na and Cl concentratio ns due to defective ion absorption . No significant differences were detected in the electrolyte concentrations between the genetically defined subgroups (25) . Our data demonstrate that patients carrying two R553X mutations present with the latest onset of P. aeruginosa infection of all genetic subgroups and that~F508/R553X compound heterozygotes show significantly later onset than do t. F508 homozygotes (Fig. IA ) . Moreover, the 3905insT mutation, localized in the second NBF of the CFTR and causing the termination of the translation six codons downstream, presents with an extremely early onset (Fig. IE and C) , high Chrispin-Norman scores (Table I ) already at the age of I y, and the greatest relative underweight (Table 2 ) and results in a more severe clinical form than all the other mutations. Although the role of P. aeruginosa colonization in the pathogenesis of lung disease in CF is still not clear (26), we found some relationship between the age at P. aeruginosa onset and a significant increase of x-ray scores in t.F508 as well as R553X homozygous patients (Table I) . These patients, respectively, whereas the mean age of patients without P. aeruginosa is 14 y (range = 8.2-25.5; n = 5) in the~FI/RX I group and 3.4 y (range = 3.3-3.5; n = 2; p = 0.05) in~F 16 patients. Homozygosity for R553X means later onset of infection ( 12.0 y; range 6.2-17.3 y; n = 3) than homozygosity for~F508 (6.7 y; range 0.2-17.4 y; n = 35).
The cumulative incidence of P. aeruginosa infection is higher in the~F2 group than in~FI /RXI patients (Fig. I A ) . In thẽ F 16 group, the prevalence of infection is higher than in~F2 results give some evidence for more rapid progression of lung disease after P. aeruginosa infection in homozygous patients.
Despite pancreatic supplementation, intestinal absorption can only be partly corrected in most of the CF patients. As initially shown (23), relative underweight (Table 2 ) is in accordance with the x-ray score (Table 1) , confirming the experience of Neijens et al. (2) that lung involvement is often linked with a decrease in body weight.
We conclude from our findings that the 3905insT mutation associated with haplotype 6 predicts a more severeclinical course than the i1F508 deletion. The hypothesis that the presence of an altered CFTR protein may be more deleterious than its total absence (15, 27) leads to the speculative suggestion that the combination of one i1F508 deletion and one 3905insT mutation will probably result in two mutant CFTR proteins trapped in the endoplasmatic reticulum and therefore acting at incorrect cellular locations (27) . The nonsense mutation R553X seems to decrease the influence of the i1F508 deletion in i1F508/R553X heterozygotes, causing a milder course and slowed progression (Fig. lA, Tables 1 and 2 ). The two compound heterozygous groups i1FI/RXI and i1FI6 indicate dominant effects of both the R553X (Fig. IB Table 1 ) mutations compared with i1F508. Several patients with both CF chromosomes carrying nonsense mutations were reported to have mild lung disease based on the argument that truncation or total absence of CFTR might be associated with nearly normal lung function (15, 28) . In their 1st decade, the three patients homozygous for R553X confirm this hypothesis. However, once affected by chronic P. aeruginosa infection, they develop rapid progression of lung disease, illustrating either that lack of the gene product may suddenly turn out to be deleterious or that homozygosity, as a consequence of doubling the same defect, may result in a more severe course than compound heterozygosity after P. aeruginosa infection.
The wide variations in each patient group, even in the i1F508 homozygotes, indicates that the severity and progression of the disease may also be determined by environmental and other genetic factors within and/or outside the CFTR gene (25, 29) . Therefore, caution is advisable in interpreting mutation analysis and in predicting the prognosis of individual patients.
On the other hand, the finding of only a few significant differences between the genetically defined subgroups may be due to the small number of patients with identical genotypes. To prove any further correlations between genotype and phenotype, we require larger patient populations-a need that is hindered by low frequencies of the remaining mutations and their markedly different geographical and/or ethnic distributions.
Although the work presented here does not permit many definitive conclusions, it is considered to be a valuable pilot study awaiting larger studies on a worldwide scale.
